BioSpace News Archive

The first Novartis executive has fallen in the wake of the $1.2 million payment to President Donald Trump’s attorney for consulting work.

Eleven Biotherapeutics is rebranding itself as Sesen Bio and investors are pleased. This morning shares of Eleven are up more than 4 percent in premarket trading.

The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.

“Imposter Syndrome” in the workplace is more than just a lack of confidence. When an otherwise competent professional feels as if he or she is incompetent, a fraud, or undeserving of the job and any accolades, promotions, or positive feedback they get, then they’re probably grappling with a good dose of imposter syndrome.

Genentech, has terminated its research program with Ames, Iowa-based NewLink Genetics.

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Evolus for its Biologics License Application (BLA) for DWP-450 (prabotulinumtoxinA), a drug to treat frown lines similar to Allergan’s Botox.

Regeneron Pharmaceuticals and its developmental partner Sanofi are eying the third quarter of this year to seek regulatory approval for Dupixent (dupilumab) as a potential monotherapy treatment for moderate-to-severe atopic dermatitis in adolescents.

Do you have anxiety at work? New study says a little workplace anxiety or stress may help you to be more successful.

Emulate, Inc. struck a deal with pharma giant AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.

EIP Pharma, based in Cambridge, Massachusetts, closed on a $20.5 million Series B financing. The round was led by Access Industries.